首页> Annals of oncology : official journal of the European Society for Medical Oncology> EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.

导出 LinkOut

翻译打印收藏纠错

第一作者： L,Fornaro

第一单位： Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa. Electronic address: lorenzo.fornaro@gmail.com.

作者： L,Fornaro ^[1] ; F,Crea ^[2] ; G,Masi ^[3] ; E,Paolicchi ^[2] ; F,Loupakis ^[3] ; F,Graziano ^[4] ; L,Salvatore ^[3] ; M,Ronzoni ^[5] ; V,Ricci ^[5] ; C,Cremolini ^[3] ; M,Schirripa ^[3] ; R,Danesi ^[2] ; A,Falcone ^[3]

作者单位： Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa. Electronic address: lorenzo.fornaro@gmail.com. ^[1] Department of Internal Medicine, Division of Pharmacology, University of Pisa, Pisa. ^[2] Department of Oncology, Transplants and New Technologies in Medicine, Division of Medical Oncology, University of Pisa, Pisa. ^[3] Medical Oncology Unit, Department of Onco-Hematology, Azienda Ospedaliera S. Salvatore, Pesaro. ^[4] Division of Medical Oncology, S. Raffaele Scientific Institute, Milano, Italy. ^[5]